FIELD: medicine.
SUBSTANCE: method involves determining γ-interferon concentration in patient blood. Γ-interferon concentration being below 170 pg/l, ursodesoxycholic acid monotherapy is indicated, Otherwise, ursodesoxycholic acid therapy is to be combined with Prednisolone and/or Azathioprine.
EFFECT: reduced risk of adverse side effects caused by Prednisolone and/or Azathioprine consumption.
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF DIFFERENTIAL DIAGNOSTICS OF AUTOIMMUNE LIVER DISEASES | 2014 |
|
RU2566723C2 |
| METHOD OF TREATING CHRONIC HEPATITIS IN CHILDREN | 2014 |
|
RU2553179C1 |
| METHOD OF TREATING AND MANAGING PREGNANT WOMEN WITH DRUG-INDUCED HEPATITIS | 2013 |
|
RU2537120C2 |
| METHOD FOR PREDICTION OF HEPATOTROPHIC THERAPY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE | 2015 |
|
RU2595827C1 |
| AUTOIMMUNE GASTRITIS PATHOANATOMICAL DIAGNOSTICS METHOD | 2023 |
|
RU2819067C1 |
| METHOD OF DIFFERENTIATING HEPATIC FIBROSIS IN CHRONIC VIRAL HEPATITIS B AND AUTOIMMUNE LIVER INJURIES | 2018 |
|
RU2701723C1 |
| METHOD OF TREATING DRUG-INDUCED LIVER INJURY IN CHILDREN SUFFERING FROM TUBERCULOSIS | 2011 |
|
RU2473346C1 |
| METHOD OF TREATING CHILDREN WITH MANIFESTATION OF LINGERING JAUNDICE IN NEONATAL PERIOD | 2009 |
|
RU2432938C2 |
| METHOD OF TREATING PATIENTS SUFFERING FROM FIRST STAGE CHOLELITHIASIS | 2012 |
|
RU2519198C2 |
| BIOTRANSPLANT AND METHOD FOR TREATMENT OF RHEUMATIC AND AUTOIMMUNE DISEASES | 2005 |
|
RU2298410C1 |
